ASCO Gastrointestinal Cancers Symposium

FDA Grants HLX22 Orphan Drug Designation for Gastric Cancer

April 6th 2025, 2:00pm

Article

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free survival and objective response.

Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer

February 20th 2025, 4:00pm

Video

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.

Lonsurf Shows Survival Benefit Over Placebo in Stage 4 Colorectal Cancer

February 10th 2025, 2:00pm

Article

In patients with residual disease after curative resection of colorectal cancer, Lonsurf showed a numerical improvement in DFS, though not significant.

Pelareorep With Chemo and Tecentriq Shows Acceptable Safety in Metastatic PDAC

February 9th 2025, 7:00pm

Article

Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

Braftovi Plus Erbitux With mFOLFOX6 May Improve Responses in BRAF V600E+ mCRC

February 8th 2025, 3:00pm

Article

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

Krazati and Erbitux Effective for KRAS G12C-Mutant Advanced mCRC

February 6th 2025, 2:00pm

Article

Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer.

Palliative Care May Reduce Invasive Intervention Use in Early-Onset CRC

February 5th 2025, 2:00pm

Article

Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders.

Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC

February 4th 2025, 8:00pm

Article

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an improvement in response rates.

Tevimbra Plus Chemo May Be Safe, Effective in Advanced Gastric/GEJ Cancer

February 3rd 2025, 10:00pm

Article

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and manageable safety in gastric/GEJ cancer.

Rybrevant Alone and in Combo With Chemo is Efficacious in Wildtype+ mCRC

February 3rd 2025, 8:00pm

Article

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.